Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasmine M Zain

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Blood|April 25, 2009
Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosionsAlexander G Marneros, Marc E Grossman, David N Silvers, et al.
Human Pathology|April 13, 2010
Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factorsFrancesca Montanari, Owen A O'Connor, David G Savage, et al.
Cancer|June 22, 2010
A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic scoreAdrienne A Phillips, Iuliana Shapira, Robert D Willim, et al.
The Lancet. Haematology|October 10, 2021
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 studyChristiane Querfeld, John A Thompson, Matthew H Taylor, et al.
Blood|March 8, 2012
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphomaSteven M Horwitz, Youn H Kim, Francine Foss, et al.
British Journal of Haematology|May 22, 2023
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphomaRobert Stuver, Steven M Horwitz, Ranjana H Advani, et al.
The Lancet. Haematology|May 28, 2021
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion studyMehdi Hamadani, Graham P Collins, Paolo F Caimi, et al.
Journal of Cachexia, Sarcopenia and Muscle|March 27, 2020
Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantationSaro H Armenian, Aleksi Iukuridze, Jennifer Berano Teh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL studyOwen A O'Connor, Barbara Pro, Lauren Pinter-Brown, et al.
Blood|June 15, 2023
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphomaMwanasha H Merrill, Parastoo B Dahi, Robert A Redd, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Blood|April 25, 2009
Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosionsAlexander G Marneros, Marc E Grossman, David N Silvers, et al.
Human Pathology|April 13, 2010
Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factorsFrancesca Montanari, Owen A O'Connor, David G Savage, et al.
Cancer|June 22, 2010
A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic scoreAdrienne A Phillips, Iuliana Shapira, Robert D Willim, et al.
The Lancet. Haematology|October 10, 2021
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 studyChristiane Querfeld, John A Thompson, Matthew H Taylor, et al.
Blood|March 8, 2012
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphomaSteven M Horwitz, Youn H Kim, Francine Foss, et al.
British Journal of Haematology|May 22, 2023
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphomaRobert Stuver, Steven M Horwitz, Ranjana H Advani, et al.
The Lancet. Haematology|May 28, 2021
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion studyMehdi Hamadani, Graham P Collins, Paolo F Caimi, et al.
Journal of Cachexia, Sarcopenia and Muscle|March 27, 2020
Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantationSaro H Armenian, Aleksi Iukuridze, Jennifer Berano Teh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL studyOwen A O'Connor, Barbara Pro, Lauren Pinter-Brown, et al.
Blood|June 15, 2023
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphomaMwanasha H Merrill, Parastoo B Dahi, Robert A Redd, et al.
Pageof 3